scholarly journals PLGA nanoparticles for the oral delivery of nuciferine: preparation, physicochemical characterization and in vitro/in vivo studies

Drug Delivery ◽  
2017 ◽  
Vol 24 (1) ◽  
pp. 443-451 ◽  
Author(s):  
Ying Liu ◽  
Xin Wu ◽  
Yushuai Mi ◽  
Bimeng Zhang ◽  
Shengying Gu ◽  
...  
2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Raghuvir H. Gaonkar ◽  
Soumya Ganguly ◽  
Saikat Dewanjee ◽  
Samarendu Sinha ◽  
Amit Gupta ◽  
...  

Author(s):  
Narendar Dudhipala ◽  
Arjun Narala ◽  
Dinesh Suram ◽  
Karthik Yadav Janga

The objective of this present study is to develop a semisolid dispersion (SSD) of zaleplon with the aid of self-emulsifying lipid based amphiphilic carriers (TPGS E or Gelucire 44/14) addressing the poor solubility of this drug. A linear relationship between the solubility of drug with respect to increase in the concentration of lipid surfactant in aqueous medium resulting in AL type phase diagram was observed from phase solubility studies. Fusion method was employed to obtain semisolid dispersions (SSD) of zaleplon which showed high content uniformity of drug. The absence of chemical interactions between the pure drug, excipients and formulations were conferred by Fourier transmission infrared spectroscopic examinations. The photographic images from polarized optical microscopic studies revealed the change in crystalline form of drug to amorphous or molecular state. The superior dissolution parameters of zaleplon from SSD over pure crystalline drug interpreted from in vitro dissolution studies envisage the ability of these lipid surfactants as solubility enhancers. Further, the caliber of TPGS E or Gelucire 44/14 in encouraging the GI absorption of drug was evident with the higher human effective permeability coefficient and fraction oral dose of drug absorbed from SSD in situ intestinal permeation study. In conclusion, in vivo studies in Wister rats demonstrated an improvement in the oral bioavailability of zaleplon from SSD over control pure drug suspension suggesting the competence of Gelucire 44/14 and TPGS E as conscientious carriers to augment the dissolution rate limited bioavailability of this active


2021 ◽  
Vol 118 ◽  
pp. 111427
Author(s):  
Akram Hasanpour ◽  
Fariba Esmaeili ◽  
Hossein Hosseini ◽  
Amir Amani

2011 ◽  
Vol 413 (1-2) ◽  
pp. 245-253 ◽  
Author(s):  
Rabea Parveen ◽  
Sanjula Baboota ◽  
Javed Ali ◽  
Alka Ahuja ◽  
Suruchi S. Vasudev ◽  
...  

2013 ◽  
Vol 102 ◽  
pp. 822-832 ◽  
Author(s):  
Anjali Singh ◽  
Iqbal Ahmad ◽  
Sohail Akhter ◽  
Gaurav K. Jain ◽  
Zeenat Iqbal ◽  
...  

2020 ◽  
Vol 46 (7) ◽  
pp. 1063-1072
Author(s):  
Busra Kandilli ◽  
Afife Busra Ugur Kaplan ◽  
Meltem Cetin ◽  
Numan Taspinar ◽  
Muhammed Sait Ertugrul ◽  
...  

Nanomedicine ◽  
2021 ◽  
Author(s):  
Samar A Rizk ◽  
Manal A Elsheikh ◽  
Yosra S R Elnaggar ◽  
Ossama Y Abdallah

Aim: The aim of this study was to elaborate on ‘bioemulsomes,' novel biocompatible lipoprotein analogs for effective lymphatic transport of baicalin (BCL). Methods: BCL bioemulsomes were developed and optimized and in vitro physicochemical characterization performed. The bioavailability of BCL bioemulsomes compared with free BCL was investigated using in vivo pharmacokinetics studies. Finally, BCL lymphatic transport was assessed via cycloheximide blockade assay. Results: Optimized BCL-loaded nanoemulsomes showed promising in vitro characteristics that favor lymphatic targeting. In vivo pharmacokinetics showed a significant improvement in bioavailability over free BCL. A significant decrease in BCL emulsome absorption (33%) was exhibited after chemical blockage of the lymphatic pathway, confirming the lymphatic transport potential. Conclusion: Bioemulsomes could be a promising tool for bypassing BCL oral delivery hurdles as well as lymphatic transport, paving the way for potential treatment of lymphoma.


Sign in / Sign up

Export Citation Format

Share Document